Fisher & Paykel Healthcare (ASX: FPH) tops gainers as FY26 result lands and tariff refund opens

Fisher & Paykel Healthcare (ASX: FPH) designs and builds the breathing humidifiers, nasal high flow systems and sleep apnea masks used in hospitals and homes across more than 120 countries. The stock led the ASX 200 gainers in early trade today after the company reported its full-year results for the year ended 31 March 2026, capping a year in which it twice upgraded guidance. The number retail investors are now watching is not the headline profit. It is the United States tariff refund, a live question that could put cash back on the balance sheet after the US Supreme Court struck down the duties that had been clipping margins all year.

What does Fisher & Paykel Healthcare actually make, and why is its business model hard to copy?

Fisher & Paykel Healthcare sits in a narrow but deep corner of medical devices. Its Hospital division builds respiratory humidification systems, breathing circuits and the consumables that go with them, anchored by Optiflow nasal high flow therapy and the F&P 950 humidification platform. Its Homecare division sells CPAP devices and masks for treating obstructive sleep apnea. Hospital products make up roughly two thirds of revenue, and the consumables attached to installed hardware generate recurring sales long after the device itself is sold.

The differentiation is the razor and blades structure layered on top of clinical adoption. Once an Optiflow system is installed in an intensive care unit and clinicians are trained on it, the hospital keeps buying single-use consumables for years, and switching to a rival means retraining staff and changing protocols. That stickiness is why the company can reinvest more than ten percent of revenue into research and development and still expand margins. New applications consumables, the newer therapy areas like anaesthesia and surgery, have been the fastest growing line within Hospital, which matters because it extends the installed base into rooms the company did not previously occupy.

The risk inside this model is concentration. The company manufactures in New Zealand and Mexico while earning around 42 percent of revenue in the United States and roughly 30 percent in Europe. That geographic mismatch between where it builds and where it sells is exactly what made the US tariff situation a genuine threat rather than a footnote, and it is the thread that runs through the rest of this year’s story.

Why did Fisher & Paykel Healthcare upgrade its FY26 guidance twice before today’s result?

The FY26 journey was a sequence of upgrades. When the company set initial guidance alongside its FY25 result in May 2025, it pointed to operating revenue of roughly NZ$2.15 billion to NZ$2.25 billion and net profit after tax of NZ$390 million to NZ$440 million, with an estimated 50 basis point drag from US tariffs baked in. At the half year in November 2025 it lifted that to NZ$2.17 billion to NZ$2.27 billion in revenue and NZ$410 million to NZ$460 million in profit. Then in February 2026 it upgraded again, to approximately NZ$2.30 billion in revenue and NZ$450 million to NZ$470 million in profit.

The pattern tells you two things. First, demand ran ahead of the company’s own conservative framing, with management citing broad based strength across the full Hospital product range in the second half. Second, a chunk of the February upgrade was foreign exchange, with the guidance rebased to a NZ:US rate of 60 cents from 57 cents at the prior mark. For a company that earns most of its revenue offshore and reports in New Zealand dollars, currency is a real swing factor, not noise, and retail investors reading the headline growth rate should separate the operational beat from the translation tailwind.

The H1 FY26 actuals showed the engine underneath. Revenue rose 14 percent to NZ$1.089 billion, the first time the company cleared a billion dollars in a single half. Net profit after tax climbed 39 percent to NZ$213 million, and gross margin expanded 110 basis points to 63 percent even after absorbing a 32 basis point hit from tariffs. The question heading into today was whether the second half sustained that pace, and the early share price reaction suggests the market liked what it saw.

What does the US Supreme Court tariff ruling mean for a possible refund to Fisher & Paykel Healthcare?

This is the part of the story that is genuinely unresolved and the reason today’s result carries more than the usual interest. Through FY26 the company paid US tariffs on hospital products it ships from New Zealand and Mexico into the United States, and those duties dragged on margins all year. Then the US Supreme Court invalidated certain tariffs that had been imposed under the International Emergency Economic Powers Act, the legal mechanism behind a slice of the duties the company had been paying.

That opened a door. Tariffs already paid under an authority later ruled invalid become candidates for refund. Management flagged in February that its guidance did not incorporate any potential refund, and that it was working through the complexities of the court rulings, the refund processes, and how free trade agreements and the Nairobi Protocol apply to its specific products. In plain terms, there may be cash owed back to the company, but the amount, the timing and the certainty were all open questions, and the company said it would update the market on tariff impacts with today’s full-year result.

For a retail investor the framing matters. A refund, if it materialises, is a one-off cash item rather than a change to the underlying earnings power of the business, so it should not be capitalised into a permanently higher valuation. But it does two useful things: it lifts reported profit in the period it lands, and it removes an overhang that has sat on the stock since the duties were introduced. The risk is the mirror image. Refund processes against a government are slow and uncertain, free trade agreement carve-outs may mean less of the company’s tariff bill qualifies than the bull case assumes, and tariff policy itself remains a moving target that could reintroduce duties through a different legal route.

How is the market pricing Fisher & Paykel Healthcare against what the newsflow implies?

Fisher & Paykel Healthcare has long traded as one of the most expensive names on the New Zealand and Australian exchanges, and that has not changed. The stock has carried a forward earnings multiple in the mid forties, a premium that reflects its consistency, its margin trajectory and a dividend record stretching back nearly two decades. Analyst fair value estimates have clustered around NZ$40 to NZ$41, with at least one major firm lifting its price target to NZ$36 from NZ$31 through the year as guidance improved.

The tension is the gap between quality and price. Few investors dispute that this is a high quality compounder with a defensible installed base and a gross margin marching toward its 65 percent target. The debate is whether a multiple in the mid forties already prices in years of that compounding, leaving little room for error. Over the twelve months into early 2026 the shares had risen only modestly and trailed the broader ASX 200, which tells you the market spent much of the year digesting that valuation rather than rerating it higher. Today’s pop is the market responding to a clean result and the prospect of tariff clarity, but the underlying question for anyone buying at these levels is unchanged: you are paying a premium multiple for predictability, and the predictability has to keep showing up.

What are the execution risks retail investors should weigh before today’s enthusiasm fades?

Several risks sit underneath the bullish read. Currency is the most mechanical. With the bulk of revenue earned in US dollars and euros and the accounts reported in New Zealand dollars, a swing in the Kiwi can flatter or flatten reported growth regardless of how many units the company sells, and part of FY26’s upgrades came from exactly this. Hedging smooths it but does not remove it.

Seasonality is the second. Hospital consumables demand in the Northern Hemisphere winter depends on how severe the respiratory season is, which means a meaningful slice of second half revenue rides on something the company cannot control. A mild flu and respiratory virus season can leave volumes softer than the run rate implies. The third is competition in the Homecare sleep apnea market, where the company competes against larger players for mask share and where pricing is more contested than in its hospital strongholds.

The fourth is the one that defines this result: tariffs. The Supreme Court ruling created the refund opportunity, but it did not end tariff risk. A different administration or a different legal mechanism could reimpose duties, the refund process could drag for years, and the company’s own framing has consistently been cautious, treating tariffs as a cost to be mitigated over time through efficiency rather than a problem that is solved. Retail investors anchoring on a refund windfall should treat it as optionality, not as a line item they can bank.

Why are investors on the ASX and NZX watching FPH as a defensive growth holding right now?

Fisher & Paykel Healthcare occupies an unusual seat in the retail conversation. It is not a speculative small cap or a meme ticker. It is a large cap quality name that retail investors and self managed super funds in Australia and New Zealand hold as a core defensive growth position, the kind of stock that gets bought on results day strength rather than traded on rumour. The interest today is driven by the result itself and the tariff refund question, both of which are concrete catalysts rather than social media momentum.

The community angle is about confirmation rather than discovery. Holders watch FPH results to check that the compounding thesis is intact, that gross margin is still climbing toward 65 percent, that the dividend is growing, and that new product adoption keeps widening the installed base. Today’s early move to the top of the gainers board is that thesis being validated in real time. For investors who do not yet hold it, the harder question is the one the valuation has always posed: this is a wonderful business, and wonderful businesses rarely trade cheaply, so the entry point is the decision, not the quality.

Key takeaways for retail investors watching Fisher & Paykel Healthcare

• Fisher & Paykel Healthcare reported its full-year FY26 result today and led the ASX 200 gainers, capping a year in which it twice upgraded guidance to approximately NZ$2.30 billion in revenue and NZ$450 million to NZ$470 million in net profit after tax.
• The live catalyst is the US tariff refund. The Supreme Court invalidated certain IEEPA tariffs the company had been paying, opening the door to a potential refund of duties, though the amount and timing remain uncertain and management has not banked it into guidance.
• The business model is a sticky razor and blades structure, with installed hospital hardware driving recurring consumables sales, gross margin expanding toward a 65 percent target, and more than ten percent of revenue reinvested into research and development.
• H1 FY26 showed the strength, with revenue up 14 percent to NZ$1.089 billion and net profit after tax up 39 percent to NZ$213 million, the first half to clear a billion dollars in revenue.
• Valuation is the central risk. The stock trades on a forward multiple in the mid forties with analyst fair value around NZ$40 to NZ$41, so buyers are paying a premium for predictability that has to keep delivering.
• Watch currency, Northern Hemisphere respiratory season severity and sleep apnea mask competition as the operational swing factors, and treat any tariff refund as one-off optionality rather than a permanent earnings uplift.